BeiGene
BGNE
#881
Rank
A$33.26 B
Marketcap
$302.96
Share price
1.71%
Change (1 day)
0.85%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : A$3.51 B

According to BeiGene 's latest financial reports the company's total liabilities are A$3.51 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31A$3.32 B13.5%
2022-12-31A$2.93 B-11.25%
2021-12-31A$3.30 B47.07%
2020-12-31A$2.24 B149.17%
2019-12-31A$0.90 B28.12%
2018-12-31A$0.70 B51.7%
2017-12-31A$0.46 B532.19%
2016-12-31A$73.39 M25.96%
2015-12-31A$58.27 M71.55%
2014-12-31A$33.96 M-40.04%
2013-12-31A$56.64 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
A$18.23 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.87 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA